NCT01464268View on ClinicalTrials.gov

Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
KeratoconusCorneal Ectasia
Interventions
DRUG

Riboflavin

Administration of riboflavin every 2 minutes for the duration of UV exposure.

DRUG

Riboflavin

Administration of riboflavin every 1 minute for the duration of UV exposure.

Trial Locations (1)

07666

Cornea and Laser Eye Institute, Teaneck

All Listed Sponsors
lead

Cornea and Laser Eye Institute

OTHER

NCT01464268 - Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia | Biotech Hunter | Biotech Hunter